DK0862633T3 - VP-antigen af JC-virus - Google Patents

VP-antigen af JC-virus

Info

Publication number
DK0862633T3
DK0862633T3 DK96941013T DK96941013T DK0862633T3 DK 0862633 T3 DK0862633 T3 DK 0862633T3 DK 96941013 T DK96941013 T DK 96941013T DK 96941013 T DK96941013 T DK 96941013T DK 0862633 T3 DK0862633 T3 DK 0862633T3
Authority
DK
Denmark
Prior art keywords
virus
antigen
analytical
diagnostic
protein
Prior art date
Application number
DK96941013T
Other languages
English (en)
Inventor
Wolfgang Lueke
Gerhard Hunsmann
Thomas Weber
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7778134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0862633(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK0862633T3 publication Critical patent/DK0862633T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
DK96941013T 1995-11-22 1996-11-22 VP-antigen af JC-virus DK0862633T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19543553A DE19543553B4 (de) 1995-11-22 1995-11-22 VP-Antigene des JC-Virus
PCT/EP1996/005177 WO1997019174A1 (de) 1995-11-22 1996-11-22 Vp-antigene des jc-virus

Publications (1)

Publication Number Publication Date
DK0862633T3 true DK0862633T3 (da) 2005-05-30

Family

ID=7778134

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96941013T DK0862633T3 (da) 1995-11-22 1996-11-22 VP-antigen af JC-virus

Country Status (9)

Country Link
US (1) US6238859B1 (da)
EP (1) EP0862633B1 (da)
JP (2) JP4456671B2 (da)
AT (1) ATE288489T1 (da)
CA (1) CA2236159C (da)
DE (2) DE19543553B4 (da)
DK (1) DK0862633T3 (da)
ES (1) ES2237778T3 (da)
WO (1) WO1997019174A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19916224C1 (de) * 1999-04-10 2000-06-21 November Ag Molekulare Medizin Synthetisches biologisch aktives Molekül
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
JP2003504014A (ja) * 1999-06-30 2003-02-04 エボテック オーアーイー アクチェンゲゼルシャフト ウイルス状粒子、それらの調製及び好ましくは薬学的スクリーニング及び機能的ゲノムにおけるそれらの使用
DE10131145B4 (de) * 2001-06-28 2005-07-14 Innovent E.V. Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
WO2005045439A1 (en) * 2003-11-07 2005-05-19 Hepgenics Pty Ltd Binding assay components
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
PT2645106T (pt) 2005-04-04 2017-09-18 Biogen Ma Inc Método para avaliar uma resposta imune a um agente terapêutico
JP2009531304A (ja) * 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
EP3620469A1 (en) 2006-02-28 2020-03-11 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
CN101437541A (zh) 2006-03-03 2009-05-20 伊兰药品公司 用那他珠单抗治疗炎性疾病和自身免疫病的方法
IL176377A0 (en) * 2006-06-18 2006-10-05 Ariella Oppenheim Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders
US20110184747A1 (en) * 2006-08-09 2011-07-28 Carmen Bozic Method for distribution of a drug
EP2054081A4 (en) * 2006-08-31 2010-07-21 Baylor Res Inst VACCINE AGAINST THE JC VIRUS
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
CN104316696A (zh) * 2009-02-05 2015-01-28 生物基因Idecma公司 用于检测jc多瘤病毒的方法
AU2010303156B2 (en) 2009-10-11 2016-02-04 Biogen Ma Inc. Anti-VLA-4 related assays
HRP20221390T1 (hr) 2010-01-11 2023-01-06 Biogen Ma Inc. Analiza za antitijela jc virusa
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
RS58967B1 (sr) * 2011-05-31 2019-08-30 Biogen Ma Inc Metod evaluacije rizika za pml
AU2012284122B2 (en) 2011-07-18 2017-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting polyomavirus-associated pathology
EP2548567A1 (en) 2011-07-22 2013-01-23 Universitätsklinikum Hamburg-Eppendorf Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
EP2554664A1 (de) 2011-08-02 2013-02-06 Life Science Inkubator Verfahren zur Aufreinigung von Virus-ähnlichen Partikeln (VLP)
EP2636746A1 (en) 2012-03-06 2013-09-11 Life Science Inkubator A novel drug delivery system based on JCV-VLP
ITTO20120570A1 (it) * 2012-06-27 2013-12-28 Pomona Ricerca Srl Anticorpo monoclonale diretto contro il virus jc
EP3312283A1 (en) 2013-03-06 2018-04-25 Life Science Inkubator Betriebs GmbH & Co. KG Drug delivery system for use in the treatment or diagnosis of neurological disorders
US10119976B2 (en) 2013-05-28 2018-11-06 Biogen Ma Inc. Method of assessing risk of PML
WO2015095770A1 (en) * 2013-12-20 2015-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic jc polyomavirus compositions and methods of use
EP2926831A1 (en) 2014-03-31 2015-10-07 Ruprecht-Karls-Universität Heidelberg CD8+ T-cell epitopes from polyomavirus capsid protein VP1 for vaccination
EP3031820A1 (en) 2014-12-08 2016-06-15 Life Science Inkubator JC Polyomavirus VLP (virus-like particle) with a targeting peptide
EP3031821A1 (en) 2014-12-08 2016-06-15 Life Science Inkubator polyomavirus VLPs with a fusion protein
EP3368694A1 (en) 2015-10-28 2018-09-05 Life Science Inkubator GmbH Use of vlp for the detection of nucleic acids
EP3670652A1 (en) 2018-12-18 2020-06-24 NEUWAY Pharma GmbH Vlp for the treatment of a lysosomal storage disease
JP6884432B2 (ja) 2018-12-18 2021-06-09 ノイウェイ ファルマ ゲーエムベーハー 新規薬物送達システムおよびそれを提供する方法
EP4153756A1 (en) 2020-05-22 2023-03-29 NEUWAY Pharma GmbH Vlp for the treatment of leukodystrophies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE296111T1 (de) * 1993-03-09 2005-06-15 Univ Rochester Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen

Also Published As

Publication number Publication date
DE59611189D1 (de) 2005-03-10
US6238859B1 (en) 2001-05-29
DE19543553B4 (de) 2009-04-09
JP2007197441A (ja) 2007-08-09
ES2237778T3 (es) 2005-08-01
CA2236159A1 (en) 1997-05-29
CA2236159C (en) 2011-03-22
JP2000500973A (ja) 2000-02-02
EP0862633B1 (de) 2005-02-02
DE19543553A1 (de) 1997-05-28
EP0862633A1 (de) 1998-09-09
WO1997019174A1 (de) 1997-05-29
ATE288489T1 (de) 2005-02-15
JP4456671B2 (ja) 2010-04-28

Similar Documents

Publication Publication Date Title
DK0862633T3 (da) VP-antigen af JC-virus
ATE328068T1 (de) Papillomavirus vakzine
DK0688227T3 (da) Fremstilling af humant papillomavirus capsidprotein og viruslignende partikler
JP2009102327A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DK1078005T3 (da) Fremgangsmåder til amyloidfjernelse ved anvendelse af anti-amyloidantistoffer
TR199801722T2 (xx) Peptit imm�nojenler.
DE59610469D1 (de) Vorrichtung zur Verabreichung von Substanzen, insbesondere Inhalationspräparate
EP0593290A3 (en) Core antigen protein of the hepatitis C virus, as well as diagnostic procedure and set of reagents.
DE60126482D1 (de) Einkettige antikörper gegen eine p53 mutante
UA35639C2 (uk) Спосіб одержання композиції очищеного капсидного білка вірусу папіломи людини
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
ITRM930818A0 (it) Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
DK0757098T3 (da) Varmebestandig maltosephophorylase, fremgangsmåde til dens fremstilling, bakterier anvendt til dens fremstilling og fremgangsmåder til anvendelse af enzymet
WO1998023752A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
DE69328488D1 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus
DE29511334U1 (de) Vorrichtung zur Verabreichung von Substanzen, insbesondere Inhalationspräparaten
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
ZA984100B (en) Process for the detection of HIV antibodies and antigens used in it.
DE755943T1 (de) Durch Antikörper gegen das C33-Antigen des Hepatitis C-Virus erkennbares Peptid